Data as of:
Price 02-03-26 16:00 ET,
Balance Sheet 2025-09-30,
Income Statement 2025-09-30,
Cash Flow 2025-09-30
Indicators
Dividend indicators
Value
Date
Pays Dividend
No
2-1-2026
Income indicators
Value
Date
EBITDA Positive
Yes
2-1-2026
Net Income Positive
No
2-1-2026
Avg CA Burn (Annual %)
-20.16%
2-1-2026
Avg CA Burn (Quarterly %)
8.99%
2-1-2026
Shares Outstanding Changes
Date
Shares Outstanding
Delta
2025-11-10
50,068,904
+1,936
2025-09-22
50,066,968
-32
Short Interest Changes
Latest short interest:
2,963,014 shares
(7.05% of float)
| Days to cover: 7.86
Date
Short Interest
Delta
Δ %
2026-02-03
2,963,014 shares
+0
+0.00%
2026-02-02
2,963,014 shares
+0
+0.00%
2026-01-30
2,963,014 shares
None
—
Interesting Volume Days
Volume/ratio use shares outstanding as of the event date (frozen).
Date
Volume
Shares Outstanding
Volume / Shares
Price
No interesting volume events
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and cryogenic biostorage within the life science industry. Its Life Sciences Products segment offers cryogenic freezers, cryogenic dewars, and accessories within the life science industry through direct sales or a distribution network. The company's products include Cryoport Express Shippers; Cryoport ELITE Shippers; Cryoport Express Cryogenic HV3 Shipping System; Smartpak II Condition Monitoring System and Tec4Med; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as CRYOGENE, a biostorage solution for the provision of pre-clinical temperature-controlled biological materials management services; and Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; CRYOPDP, a temperature-controlled logistics solution; MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; and Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.